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ABSTRACT
Objectives: Cost-of-illness (COI) studies estimate the overall
economic burden of a speciﬁc disease, rather than simply
treatment-related costs. While having been criticized for not
allowing resource prioritization, COI studies can provide
useful guidance, so long as they adhere to accepted method-
ology. Prostate cancer is an important disease in terms of
economic implications because of its increasing incidence and
health-care costs and therefore provides a relevant example
with which to review COI study methodologies. The aim of
this study was to review published COI studies on prostate
cancer to analyze the methods used.
Methods: First, we provide a general description of the COI
method. COI studies relating to prostate cancer were then
systematically reviewed, focussing on an analysis of the dif-
ferent methods used.
Results: The methods, data sources, and estimated cost cat-
egories in each study varied widely. The review showed that
COI studies adopted signiﬁcantly different approaches to
estimate the costs of prostate cancer, reﬂecting a lack of
consensus on the methodology of COI studies in this area.
Conclusion: To increase its credibility, closer agreement
among researchers on the methodological principles of the
COI studies would be desirable.
Keywords: cost-of-illness, economic evaluation, prostate
cancer.
Introduction
Cost-of-illness (COI) studies aim to describe the eco-
nomic burden of a speciﬁc disease to society. They are
designed to evaluate not only the costs attributable to
the treatment of a particular illness, but also actual
illness-related global costs [1]. In principle, they should
either inform the most accurate choices in resource
allocation or be used in full economic evaluations
of health-care programs and treatments [2,3]. COI
studies have been criticised for not really providing
useful information or enabling choice of priorities
[1,4]. COI studies can, however, play an important
role in informing cost estimates for use in further eco-
nomic evaluations [5,6]. These studies should be
carried out in accordance with a clear and widely
accepted methodology [5,7].
Prostate cancer is a major public health problem in
Western countries [8]. It is the most common cancer
among men in North America with over 180,000 cases
in the United States per year, accounting for almost
one-third (31.2%) of all annual cancer cases [9]. Pros-
tate cancer ranks second after lung cancer as the under-
lying cause of cancer death in men, accounting for
11.7% of the cancer deaths nationally among men.
Treatment varies depending on the stage and grade.
For localized cancer, the treatment options include
activemonitoring orwatchful waiting, radical prostate-
ctomy, radical radiotherapy, and more recently brachy-
therapy. In advanced disease, they include hormone
manipulation, with most patients receiving luteinizing
hormone releasing hormone (LHRH) analogs. In addi-
tion, a few patients may undergo orchidectomy or may
receive antiandrogen therapy. Chemotherapy for ad-
vanced prostate cancer is used in a few patients. In
patients treated for early stage prostate cancer, long-
term studies have not shown a signiﬁcant difference
between surgical and radiation therapies. The Ameri-
can Urological Association’s prostate cancer clinical
guidelines panel was unable to make treatment re-
commendations [10]. In patients treated for locally
advanced prostate cancer, the ideal treatment is contro-
versial [11]. Health-care costs are expected to rise
because of an older population and earlier detection of
the disease [12]. Given the increasing incidence of
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prostate cancer and the uncertainty surrounding its
management and its treatment, there is growing
concern that the future burden of disease may be sub-
stantial [13,14].
The aim of this study was to review relevant pub-
lished COI studies to analyze the methods used. First,
we provided a general description of the COI method.
We then systematically reviewed the studies on cost
relating to prostate cancer, analyzing the different
methods used.
Methods
COI
To conduct a COI study, it is necessary to ﬁrst deﬁne
the pathological state, the epidemiological approach,
the type of costs to be assessed, and, thus, the perspec-
tive of the study. Subsequently, data on resource con-
sumption and unit costs can be gathered, and results
presented and methodically discussed, in conjunction
with sensitivity analysis to test their robustness.
Deﬁning the disease and the patient. Disease deﬁni-
tions are subject to interpretations, so COI studies
should precisely deﬁne the disease state investigated,
including the identiﬁcation of subgroups of patients
according to clinical and economic criteria. This makes
the analysis more precise and relevant.
Epidemiological approach. In COI studies,
prevalence- or incidence-based approaches may be
adopted. The prevalence-based approach requires an
analysis of the costs for each stage of the disease before
being applied in economic evaluations. On the other
hand, incidence-based COI studies generally establish
lifetime cost estimates that could be directly incorpo-
rated in a cost-effectiveness analysis or a disease model
to evaluate future costs. Nevertheless, as change in the
health-care sector is rapid, long-term estimates are not
very reliable.
Perspective of the analysis and costs assessed. Differ-
ent types of costs (direct, indirect, intangible) are
included in economic evaluations, depending on the
study’s point of view (e.g., the health-care system per-
spective only takes the direct health-care costs incurred
by the payer into account whereas the societal perspec-
tive also considers indirect costs and costs to be met by
the patients and their families).
Estimating resource consumption. Methods for esti-
mating resource consumption vary, depending on
available data. A prospective approach (e.g., from
medical records or clinical trials) is preferable with
a retrospective approach because of the bias risk and
the quality data [15]. Nevertheless, when available
data are limited, the retrospective approach can be the
only method to calculate costs. For the retrospective
approach, the activity data can be collected either
using aggregate ﬁgures from hospital admissions, con-
sultations, mortality, etc. (“top down” method) or by
referring to the records of a sample of patients
(“bottom up” method).
Valuation of unit costs. Costs should represent the
value of the input in its best alternative use, i.e., the
opportunity cost. In a well-functioning, competitive
market, this would be the minimum price required to
use the input in its current use rather than in an alter-
native use [3,16].
Direct costs can be estimated via per capita expen-
diture, national tariffs, market prices, data from pub-
lished studies and speciﬁc estimates and other
methods, depending on study design. An alternative to
using patients’ charges and tariffs, which do not accu-
rately estimate underlying costs, is to consider the costs
based on accounting principles and estimated by
health-care centers or hospitals, with a clear speciﬁca-
tion of methodology to account for overhead costs.
Medical-care costs are characterized by certain
distributional properties. Failure to account for these
issues will result in a biased estimated of cost and
misguided conclusions of the study. Censoring data is
recognized as an issue that can bias cost studies.
Estimates of indirect costs frequently use the human
capital approach, based on the principle of productive
potential [17,18]. A variation, the friction cost method
[2,3], aims to overcome a potential overestimation
of indirect costs and assumes that, in the absence of
full employment, indirect costs occur only during the
period of time necessary to restore the initial level of
production (friction period). Because production losses
because of mortality are not considered, future lost
earnings are neglected [18,19]. This method is seldom
applied as it requires a huge amount of information.
Discounting costs. Discounting converts future cur-
rencies to their present value and is frequently applied
when COI studies are considered over several years.
The choice of a discount rate originates from the social
opportunity cost approach, but it has increasingly been
viewed as a general statement about social time pref-
erence [3]. The following equation is applied to esti-
mate costs:
C C ra t
n
t
n
= +( )
=
−∑
1
1
Where: Ca = present value of cost strategy, Ct = value
of cost strategy in year t, r = discount rate, t = time
period.
Sensitivity analysis. Sensitivity analysis of the key vari-
ables (e.g., disease incidence, survival probabilities,
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unit costs) tests the robustness of the results. A sensi-
tivity analysis can take various forms: simple, multi-
way, and probabilistic [20]. It seems particularly
interesting to perform a sensitivity analysis using dif-
ferent methods to estimate the various types of costs.
Presentation of results. The presentation of COI
results should be consistent with collected data and
should break down results into as many components
as possible with full explanation given for clarity.
Literature Review
Study selection. A bibliographic search was performed
on an international medical literature database
(Medline, from 1966 until November 2006). All
studies which assessed the economic burden of pros-
tate cancer were selected. Two combinations using
keywords were carried out (“prostate cancer” and
“cost-of-illness”; “prostate cancer” and “economic
evaluation”). A total of 224 abstracts were ﬁrst
selected; 31 of them underwent a subsequent full
article reading, thus providing 15 articles.
National datasets are appropriate for common ill-
nesses, such as cancer and other disease with high
prevalence rates [21]. We limited the search to nation-
ally published studies. All studies assessing the eco-
nomic burden of prostate cancer at a national level and
published in a peer-reviewed journal were selected.
Sixteen studies were excluded because they did not
assess the economic burden at a national level. One
study was carried out in California. In this special case,
California was considered a country because of its
population, extent, economy, and wealth. Additional
publications were identiﬁed from the reference list of
published articles. The aim of this study was to assess
the methods adopted by the authors rather than to
compare cost estimates.
Study review. A systematic review was performed.
One author (L. Molinier) selected abstracts. Four
methodologists (E. Bauvin, C. Castelli, C. Combes-
cure, and L. Molinier) each read the 31 articles
retrieved by the search strategy and reviewed the 15
selected articles. In keeping with the key methodologi-
cal points identiﬁed in the ﬁrst part of the article, they
asked questions based on existing checklists for full
economic evaluations [3,22]. An equal weight was
given to each item. The ﬁnal score was the sum of the
10 individual items. The objective was not to establish
a hierarchy in the criteria used by allocating them
different weights, but to use these criteria to analyze
the methods used. Each study was assessed separately
by the reviewers. Finally, a meeting to review the
outcome was called and a consensus was reached by
discussion. For each item, an agreement between the
reviewers was found. Then, all authors, both clinicians
and methodologists, discussed the results.
Results
Fifteen studies met our criteria (Table 1). Nine studies
were carried out in Europe [12,23–30] and six in
North America [10,14,31–34]. Eleven studies selected
a sample ranging in size from 28 to 72,043 patients
[10,12,23,25,28–34]. One study assessed costs starting
from consultations, prescriptions, and bed days for
treatment [26]. Three studies modeled costs without
including patients [14,24,27].
Deﬁning the Disease
The deﬁnition of prostate cancer is based on histologi-
cal cell type provided by the biopsies, and is completed
by nuclear differentiation (Gleason score) and the stage
of the disease. Eleven studies gave a precise deﬁnition
of prostate cancer [10,12,14,23,25–29,31,32]. One
study was limited to screen prostate cancer [27], and
another to early stage prostate carcinoma [10]. One
study took into account men who underwent radical
prostatectomy [32]. One study quantiﬁed medical
costs associated with prostate cancer with bone
metastasis [29].
Epidemiological Approach
Eleven studies followed an incidence-based approach
[10,12,14,23,25,27–29,31,32,34]. Three studies cal-
culated prevalence-based health-care costs [26,30,33].
In one study, costs were linked to incidence and preva-
lence [24]. Incidence and prevalence data were mainly
estimated from national surveys.
Perspective of the Analysis and Costs Assessed
Three studies did not specify the viewpoint adopted
[24,25,27]. Studies carried out in Europe adopted
mainly the health-care payer’s perspective
[12,23,26,28,30] and US studies the Medicare’s per-
spective [10,31–34]. The costs analysis was performed
from the hospital point of view in a Dutch study [29].
Two studies quantiﬁed both direct and indirect
costs [33,34]. Max et al. estimated that indirect costs
accounted for 50% of total costs [33]. In the second
study, authors presented results limited to monthly
indirect costs [34]. All other studies quantiﬁed only
direct costs.
Direct costs considered by most studies included
in- and outpatient care in relation to initial diagnosis
and treatment (with surgery, radiotherapy, and drugs).
Eight studies took into account terminal care costs
[12,14,23–25,28,30,31].
Estimating Resource Consumption
All studies estimated resource consumption retrospec-
tively. Eight studies used a bottom-up approach to
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gather activity data [10,12,23,25,28,29,31,32]. In
three Swedish studies, all procedures in institutional
and noninstitutional care were registered per patient
[12,23,28]. The clinical records of 101, 128, and 204
patients were analyzed in these studies, respectively
[12,23,28]. In two studies, a full audit of resource-
using hospital events was compiled for each patient
[25,29]. A total of 719 medicals records of patients
diagnosed in the County of Aarhus were available for
analysis in the Danish study [25]. In the Dutch study,
28 patients were selected (14 in a community hospital
and 14 in a university medical center) [29]. Data on
resource utilization were collected by means of patient
chart research and data from the hospital information
system. Three American studies analyzed all claims
submitted to Medicare for 72,043, 5016, and 10,107
patients, respectively [10,31,32].
Seven studies used the top-down approach
[14,24,26,27,30,33,34]. Resource consumption was
estimated using mainly published national indicators,
data from national surveys and published studies. The
use of top-down approaches to assess resource con-
sumption implies aggregate data processing, which, if
not properly performed, could induce errors and unre-
alistic results. It was not always obvious to determine
how data on resource consumption were processed to
obtain more detailed data. One study used a Markov
state-transition simulation model, the Montreal Pros-
tate Cancer Model, to estimate costs [14].
The studies collected information over various
periods. The follow-up was 1 year in the three studies
which adopted a prevalence-based approach
[26,30,33]. When costs were linked to incidence, the
follow-up ranged from 6 months until 17 years
[10,14,29,31,32,34] or included the whole period of
disease from diagnosis to death [12,23–25,28]. One
study did not specify the follow-up period [27].
Valuation of Unit Costs
Different methods, mainly extrapolations from
national sources and published data, were adopted to
assess direct costs. Swedish studies calculated costs
from the ﬁnancial accounting system of regional ser-
vices and the pharmacy sales prices [12,23,28,30]. One
Dutch study used data extracted from national hospi-
tal registers and published studies [24]. The other
Dutch study took into account costs calculated in two
hospitals (a community and a university hospital), the
Dutch tariff system for diagnostic tests and wholesale
drug prices [29]. No information relating to the valu-
ation of unit costs is reported in the Danish study [25].
American studies estimated costs mainly from Medi-
care payments [10,31–34]. Two studies also included
insurer payments [33,34]. The Canadian study valued
inpatient costs from the national indicators of the
Canadian Institute for Health Information and costs of
diagnostic tests from the Quebec and Ontario reim-
bursement schedules; drug costs were provided by IMS
Canada [14]. The English study determined unit costs
with the UK NHS data [26]. The French study esti-
mated inpatient costs with per diem tariffs applied in
two university hospitals and billed charges in two
clinics; outpatient costs were calculated on the basis of
French Social Security tariffs [27]. No study took into
account distributional properties of medical-care costs
and censoring data.
Two studies quantiﬁed indirect costs [33,34]. They
were estimated by the human capital approach. One
study assessed the mortality costs [33] and the other
the morbidity costs [34]. To value the lost productiv-
Table 2 Answers to the methodological questions by study
Questions/answers
All
studies
Borre
et al. [25]
Chamberlain
et al. [26]
Haillot
et al. [27]
Koopmanschap
et al. [24]
Groot
et al. [29]
Carlsson
et al. [23]
Holmberg
et al. [28]
Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No
1 Was a clear deﬁnition of the
illness given?
11 4 0 Yes Yes Yes P Yes Yes Yes
2 Were epidemiological sources
carefully described?
13 1 1 Yes Yes No Yes P Yes Yes
3 Were direct/indirect costs
sufﬁciently disaggregated?
8 5 2 Yes P P No Yes Yes Yes
4 Were activity data sources
carefully described?
14 1 0 Yes Yes P Yes Yes Yes Yes
5 Were activity data appropriately
assessed?
13 0 2 Yes Yes No Yes No Yes Yes
6 Were the sources of all cost
values analytically described?
8 6 1 No Yes Yes P Yes P P
7 Were unit costs appropriately
valued?
12 1 1 NS Yes No P Yes Yes Yes
8 Were the methods adopted
carefully explained?
7 6 2 No Yes No P Yes P P
9 Were the major assumptions
tested in a sensitivity analysis?
0 0 15 No No No No No No No
10 Was the presentation of study
results consistent with the
methodology of the study?
13 2 0 P Yes P Yes Yes Yes Yes
Total score by study 99 26 24 5 1 3 8 1 1 2 3 5 4 4 2 7 1 2 7 2 1 7 2 1
Total score by study is the sum of answers.
NS, not speciﬁed; P, partially.
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ity resulting from premature death, the Californian
study considered life expectancy for different age
groups, changing pattern of earnings at successive
ages, varying labor force participation rates, and an
imputed value for housekeeping services [33]. A dis-
count rate of 3% was used to convert the stream of
lifetime earnings into present value equivalent. Indi-
rect costs of US$ 180 million accounted for 50% of
total estimated costs [33]. In the second study, indi-
rect costs were measured by days absent from work
and short-term disability days per month [34]. A
daily wage was assigned to each study patient by
matching to average Bureau of Labor Statistics wages
by sex, age category, and geographic region. Indirect
cost analysis was performed on an aggregate level,
i.e., on several tumor types (brain, colorectal, lung,
ovarian, pancreatic, prostate, and non-Hodgkin’s
lymphoma). The mean monthly costs were US$ 698
and US$ 373 for short-term disability and absentee-
ism, respectively.
Discounting Costs
Costs were discounted in six studies
[12,14,23,28,31,33]. The discount rates chosen were
properly explained. Nevertheless, one study did not
specify the rate value [31]. The time horizon was short
(2 years) in the studies where costs were not
discounted.
Sensitivity Analysis
No study analyzed and discussed the variables which
have a signiﬁcant impact on cost estimates.
Presentation of Results
Most studies presented results clearly. They were
mainly well explained and consistently set out in rela-
tion to the methods adopted. Nevertheless, one study
presented cost results without deﬁning the cost analy-
sis method [25], and two studies did not fully explain
the reasons for certain major assumptions which
appeared questionable [24,27]. A further two studies
did not differentiate costs, thus reducing the strength
of the information provided [24,34].
All studies presented results in terms of cost per
patient with two studies proposing predicted costs
[14,24].
According to the key methodological points, we
have drafted a checklist of questions related to the
eight items analyzed (Table 2). For 10 studies, the
answers to seven of 10 questions were “yes”
[10,12,14,23,26,28,29,31–33], and for one question,
all studies were scored “no” (Table 2).
Discussion
This study reviewed 15 COI studies on prostate cancer
with the main goal of analyzing the various method-
ologies. According to the key methodological points,
10 studies were scored’yes’ on the majority of the
questions [10,12,14,23,26,28,29,31–33].
Studies analyzed here conﬁrm that prostate cancer
is a costly illness, and suggest that indirect costs
account for a large share of total costs (Table 1). Hos-
pitalization and treatments accounted for a large part
of direct costs.
Nevertheless, commenting on these quantitative
results is problematic because signiﬁcantly different
approaches had been adopted to estimate the costs of
prostate cancer. There were also marked differences in
the types of costs included and the sources used to
assess activity data. Therefore, the comparison of the
results reported in each study is not very useful. The
Sennfält
et al. [12]
Norlund
et al. [30]
Grover
et al. [14]
Riley
et al. [31]
Litwin
et al. [32]
Brandeis
et al. [10]
Max
et al. [33]
Chang
et al. [34]
Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No
Yes P Yes Yes Yes Yes P P
Yes Yes Yes Yes Yes Yes Yes Yes
Yes P Yes P P Yes Yes No
Yes Yes Yes Yes Yes Yes Yes Yes
Yes Yes Yes Yes Yes Yes Yes Yes
P P Yes Yes Yes Yes Yes P
Yes Yes Yes Yes Yes Yes Yes Yes
P P Yes Yes Yes Yes Yes P
No No No No No No No No
Yes Yes Yes Yes Yes Yes Yes Yes
7 2 1 5 4 1 9 0 1 8 1 1 8 1 1 9 0 1 8 1 1 5 3 2
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methods used to estimate disease costs vary widely
across studies in the literature, which is probably due
to the lack of consensus on the methodology. There-
fore, the deﬁnition of standards, with a large consensus
in the methodology selected to conduct these studies
should be a major concern for the scientiﬁc community
[35,36]. Bloom et al. proposed, in a ﬁrst step, to imple-
ment guidelines to standardize methods and study
design for COI studies [37]. Nevertheless, we must
bear in mind that, unlike clinical trial results, it is very
difﬁcult to generalise quantitative results of economic
studies conducted in different countries. Economic
results are difﬁcult to compare on account of monetary
issues, such as ﬂuctuating exchange rates and different
purchasing powers of currencies. Domestic character-
istics also dramatically affect resource consumption
and unit costs, including differences in clinical practice
and the health-care system framework.
As several studies did not fully explain their
methods, they were difﬁcult to assess. This might be
due to a general lack of economic awareness in the
medical journals that support economic studies. Most
of the studies reviewed were published in journals that
did not demand sufﬁciently detailed and explicit expla-
nation of the methodologies selected. No study con-
ducted a sensitivity analysis. This is not a standard
practice across COI studies in cancer settings. As an
example, in lung cancer, a sensitivity analysis was per-
formed in three COI studies [38–40]. In 1996, the
British Medical Journal published guidance informa-
tion to authors and peer reviewers on economic evalu-
ations, but it did not address COI studies [41]. A
detailed description of the methodological choices
would improve the credibility of COI studies.
Conclusion
Cost-of-illness studies can provide information to
support the political process as well as the manage-
ment functions at different levels of health-care orga-
nizations. These studies must be capable of identifying
the actual clinical management of illness and measur-
ing the true cost.
Cost-of-illness study results can serve as a baseline
for further economic evaluations. Nevertheless, an
insufﬁcient description of methods may lead to misun-
derstandings. The COI studies of prostate cancer iden-
tiﬁed in this review highlight the poor consensus of
methodological approaches, perhaps reﬂecting a lack
of stringency on the part of medical journals. Hence,
journals should encourage researchers to give clear
descriptions and discuss limitations, and a further
effort should be made to validate methodology.
The viewpoint of the analysis must be stated.
Resource consumption could be better estimated by
the follow-up of a sample of patients, and unit costs of
the facilities provided for patients’ care could be care-
fully assessed.
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